Drug Doses & Preparation | Complete professional monograph and nursing note sheet
Ceftriaxone sodium is a third-generation cephalosporin for susceptible bacterial infections. Select dose, route, duration and combination therapy by diagnosis, microbiology, patient age and local antimicrobial policy. The numerical preparation tables below are specific to the cited US vial label: verify the actual Indian vial insert before use.
Quick note sheet
- Powder vials: 250 mg, 500 mg, 1 g, 2 g (product-dependent).
- Adult usual: 1–2 g/day IV or IM, once daily or divided q12h; label maximum 4 g/day.
- IV 1 g preparation (cited vial): add 9.6 mL compatible diluent, yielding approximately 100 mg/mL; withdraw dose and further dilute to 10–40 mg/mL.
- IV infusion: 30 minutes; neonatal infusion 60 minutes only where use is permitted and specialist-authorised.
- IM 1 g preparation (cited vial): add 3.6 mL approved IM diluent to yield approximately 250 mg/mL; deep IM in a large muscle.
- Never mix with calcium-containing IV fluids. Neonatal contraindications must be checked before any dose.
Clinical role and indications
Indications in the cited label include susceptible lower respiratory, urinary tract, skin/soft tissue, intra-abdominal (with appropriate anaerobic coverage), bone/joint and other serious bacterial infections, plus selected meningitis and gonococcal indications. Current syndrome-specific guidelines and local resistance patterns may require different regimens or alternatives. Do not use for undifferentiated fever or viral illness.
Formulations and Indian availability
| Form | Labelled strength | Practical caution |
|---|---|---|
| Powder for injection | 250 mg | Check whether approved for IV, IM or both |
| Powder for injection | 500 mg | Read supplied solvent label |
| Powder for injection | 1 g | Reconstitution volume differs by route |
| Powder for injection | 2 g | Confirm vial type and final concentration |
India’s National Pharmaceutical Pricing Authority lists ceftriaxone injection strengths including 250 mg and 1 g; that historical price listing is not proof of current stock. Indian brand names and pack photographs are omitted until a current manufacturer/market source verifies them. Ceftriaxone–sulbactam and other combinations are not interchangeable with ceftriaxone alone.
Adult dose by indication
| Situation | Label-based regimen | Checks |
|---|---|---|
| Susceptible bacterial infection, usual adult | 1–2 g/day IV/IM once daily or in 2 equal doses q12h; maximum 4 g/day | Site, severity, culture, renal/hepatic status and guideline |
| Severe or CNS infection | Do not assume usual dose is sufficient; use indication-specific meningitis protocol and specialist review | Organism, susceptibility and adjunctive treatment |
Paediatric dose by indication
| Indication | Cited-label regimen | Limit |
|---|---|---|
| Skin/skin-structure infection | 50–75 mg/kg/day once daily or divided q12h | Maximum 2 g/day |
| Serious infection other than meningitis | 50–75 mg/kg/day divided q12h | Maximum 2 g/day |
| Acute bacterial otitis media, selected cases | 50 mg/kg IM once | Maximum 1 g |
| Bacterial meningitis | Initial 100 mg/kg (max 4 g), then 100 mg/kg/day once daily or divided q12h | Maximum 4 g/day; usual 7–14 days according to organism/response |
Neonatal safety: premature and hyperbilirubinemic neonates have important contraindications; ceftriaxone is contraindicated in neonates 28 days or younger who require or are expected to require IV calcium-containing solutions. Do not extrapolate older-child dosing to neonates.
Nursing preparation: IV vial reconstitution
The following is from one conventional ceftriaxone powder-for-injection label, not a universal instruction for every vial.
| Vial | Compatible IV diluent added | Approximate resulting concentration |
|---|---|---|
| 250 mg | 2.4 mL | 100 mg/mL |
| 500 mg | 4.8 mL | 100 mg/mL |
| 1 g | 9.6 mL | 100 mg/mL |
| 2 g | 19.2 mL | 100 mg/mL |
- Check patient, prescription, indication, allergy, age, weight, laboratory data, product identity and expiration.
- Confirm the vial’s own route-specific reconstitution table and permitted diluent; do not use calcium-containing fluids.
- Reconstitute aseptically and inspect for particulates or damage.
- Withdraw the prescribed milligram dose based on the verified final mg/mL concentration.
- Further dilute with compatible IV fluid to a final concentration of 10–40 mg/mL where the cited label applies. Calculate final total volume, not simply volume added.
- Label the preparation and administer by controlled infusion over 30 minutes (60 minutes for neonates only if an appropriate specialist-authorised indication exists).
- Record administration and assess for immediate hypersensitivity.
Worked IV calculations (educational, not an individual order)
Example A: Prescribed 1 g; reconstituted concentration approximately 100 mg/mL; withdraw approximately 10 mL. If prepared to a final volume of 50 mL, final concentration is 20 mg/mL. Over 30 minutes, pump rate = 100 mL/hour. Verify whether this concentration, container and fluid are approved for the actual product.
Example B: A verified paediatric prescription of 750 mg and verified 100 mg/mL solution gives 7.5 mL withdrawal. At final volume 30 mL, concentration is 25 mg/mL; over 30 minutes pump rate = 60 mL/hour. This is arithmetic only; confirm age, indication, dose ceiling and fluid allowance independently.
IM reconstitution and administration
| Vial | Diluent for approximately 250 mg/mL |
|---|---|
| 250 mg | 0.9 mL |
| 500 mg | 1.8 mL |
| 1 g | 3.6 mL |
| 2 g | 7.2 mL |
For the cited 1 g vial, approximately 250 mg/mL means 1 g corresponds to approximately 4 mL after reconstitution. Inject deep into a sufficiently large muscle using age/size-appropriate site selection and institutional policy; assess volume per site. If lidocaine is supplied or used as an IM solvent, that solution must NEVER be administered intravenously. Check lidocaine contraindications and the exact manufacturer’s instructions. Do not use an IV reconstitution table for IM injection.
Compatibility, storage and stability
Never use Ringer’s, Hartmann’s or another calcium-containing IV diluent. Do not administer simultaneously through a Y-site with IV calcium-containing solutions. In patients other than neonates, sequential administration may be permitted with thorough flushing using a compatible fluid, per label and hospital policy. Other drugs may be incompatible in admixture. Stability and beyond-use times depend on diluent, concentration, container, temperature and product; consult the actual vial label and pharmacy policy rather than assigning a universal expiry.
Renal/hepatic considerations
The cited label generally does not require dose adjustment for isolated renal or isolated hepatic impairment at standard doses, but combined severe renal and hepatic dysfunction requires close monitoring and a lower ceiling according to the product label. Dialysis and critical illness require individual assessment. Monitor clinical response and laboratory data.
Pregnancy and lactation
Use only for a supported bacterial indication after assessing maternal benefit, available human pregnancy data and alternatives. Ceftriaxone can enter breast milk in low amounts; consider infant gastrointestinal effects, allergy and the infant’s condition. Check current product information and obstetric/paediatric advice.
Contraindications and important interactions
- Serious ceftriaxone or relevant cephalosporin hypersensitivity; assess severe immediate beta-lactam reactions.
- Premature/hyperbilirubinemic neonates and neonates needing IV calcium as described above.
- IV calcium-containing fluids: precipitation risk.
- Review anticoagulants, other antimicrobials and all infusion-line compatibility with the pharmacist.
Monitoring and adverse effects
- Clinical response, cultures and antimicrobial de-escalation.
- Rash, anaphylaxis, diarrhoea and possible C. difficile infection.
- Blood count and liver/renal tests when prolonged or clinically indicated.
- Biliary sludge/pseudolithiasis, hemolytic anemia and other serious adverse reactions.
- IV site phlebitis and IM injection-site pain.
Limitations
This guide does not replace a current Indian manufacturer insert, neonatal formulary, syndrome-specific infectious-disease guideline or local stewardship protocol. It does not establish current Indian brand availability, universal site-specific maximum IM volume or universal post-reconstitution stability. Do not use it alone to prepare or prescribe a patient dose.
Primary references
- DailyMed: Ceftriaxone for Injection, USP — dosage, preparation, contraindications and compatibility
- National Pharmaceutical Pricing Authority, India: ceftriaxone listed formulations (historical pricing)
Last reviewed: 10 October 2026
Medical disclaimer: For qualified health professionals. Independently verify patient-specific prescription, current product label, clinical protocol, dilution, concentration, compatibility and administration before use.